The ageing of people living with cystic fibrosis : what to expect now?
Felipe Montiel, Almudena (Vall d'Hebron Institut de Recerca (VHIR))
Fernández, Antonio Álvarez (Vall d'Hebron Institut de Recerca (VHIR))
Culebras Amigo, Mario (Vall d'Hebron Institut de Recerca (VHIR))
Traversi, Letizia (Vall d'Hebron Institut de Recerca (VHIR))
Clofent, David (Vall d'Hebron Institut de Recerca (VHIR))
Reyes, Karina Loor (Vall d'Hebron Institut de Recerca (VHIR))
Polverino, Eva (Vall d'Hebron Institut de Recerca (VHIR))

Data:	2024
Resum:	The prognosis of people with cystic fibrosis (pwCF) has improved dramatically with the introduction of cystic fibrosis transmembrane conductance regulator (CFTR) modulators (CFTRm). The ageing of the cystic fibrosis (CF) population is changing the disease landscape with the emergence of different needs and increasing comorbidities related to both age and long-term exposure to multiple treatments including CFTRm. Although the number of pwCF eligible for this treatment is expected to increase, major disparities in care and outcomes still exist in this population. Moreover, the long-term impact of the use of CFTRm is still partly unknown due to the current short follow-up and experience with their use, thus generating some uncertainties. The future spread and initiation of these drugs at an earlier stage of the disease is expected to reduce the systemic burden of systemic inflammation and its consequences on health. However, the prolonged life expectancy is accompanied by an increasing burden of age-related comorbidities, especially in the context of chronic disease. The clinical manifestations of the comorbidities directly or indirectly associated with CFTR dysfunction are changing, along with the disease dynamics and outcomes. Current protocols used to monitor slow disease progression will need continuous updates, including the composition of the multidisciplinary team for CF care, with a greater focus on the needs of the adult population. The ageing CF population brings new challenges: emerging comorbidities and uncertain long-term effects of CFTR modulators. Early treatment is crucial, but the evolving landscape requires constant updating of care. https://bit. ly/3AevNrX.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	European Respiratory Review, Vol. 33 (october 2024) , ISSN 1600-0617

DOI: 10.1183/16000617.0071-2024
PMID: 39477350

20 p, 656.8 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats